ASND

252.7301.26%
LH

Lars Holtug

Independent Director

Mr. Lars Holtug, M.Sc., has been Independent Director at Evaxion A/S (formerly known as Evaxion Biotech A/S) since May 25, 2021. He has been Director of Ascendis Pharma A/S since November 2, 2018. Mr. Holtug was a partner at PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (?PWC?) from 1993 to 2015. Previously, he was also Chairman of PWC in Denmark from 2005 to 2009. During his tenure at PWC, Mr. Holtug was responsible for auditing various large publicly-listed pharmaceutical and biotech companies in the U.S. and Denmark. He was also an advisor to a number of PWC clients. From 2004 to 2015, Mr. Holtug was a member of the Danish Commercial Appeals Board (?Erhvervsanken?vet?) and a board member of the Danish Company law association (?Dansk Forening for Selskabsret?). He was also a member of the Accounting Standards Board of the Federation of State Authorized Accountants in Denmark (?Foreningen af Statsautoriserede Revisorer? or ?FSR?) from 1998 to 2002, where he was previously a member of the Auditing Standards Board. He serves as Director of MTI Caretag Invest ApS. He serves as Director of Domus Insurance/Frida Forsikringsagentur and LH2022 ApS. He served as Director of Adform A/S from 2017 to 2019. Currently, Mr. Holtug serves as chairman of Gaming Investment A/S and its 10 subsidiaries, and of Valizo Aps. Mr. Holtug holds an M.Sc. from Copenhagen Business School and is educated as a state authorized public accountant in Denmark.

Positions